Unicycive Therapeutics Inc (UNCY) Stock Price, Quote & News

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, li...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 351 4495

Website: unicycive.com

Address:

4300 El Camino Real, Suite 210, Los Altos, United States

donkeykongreturns Aug. 22 at 1:52 AM

$UNCY I would never put my money within 10,000 miles of this sh*tbox, but people who are in this need to wake up. How many Lanth Carb pills does the market truly need? These guys have been taking you for a ride the whole time.

0 · Reply

Earth4thewin Aug. 21 at 4:18 PM

$UNCY to all those that got scared into selling their shares on the last dip 😔

0 · Reply

anan1 Aug. 21 at 3:12 PM

$UNCY When is the next dilution Gupta? He needs to go to Jail.

0 · Reply

Howdy123_ Aug. 21 at 2:53 PM

$UNCY they're waiting for any run up to dilute into

0 · Reply

Howdy123_ Aug. 21 at 2:02 PM

$UNCY this thing looks like it's about to drop down a cliff

0 · Reply

Howdy123_ Aug. 21 at 1:39 PM

$UNCY they're probably at 23 million outstanding shares now

0 · Reply

Howdy123_ Aug. 21 at 1:35 PM

$UNCY Dowwwwwwwwn it goes

0 · Reply

zawojak Aug. 21 at 6:30 AM

$UNCY never fails to disappoint, as good as management.

0 · Reply

TheYoungGeologist Aug. 20 at 9:56 PM

$UNCY

0 · Reply

Howdy123_ Aug. 20 at 8:08 PM

$UNCY we have a runner -- ending up +0.5% 🙏🙏. Great job UNCY team

1 · Reply

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.

Aug 20, 2025, 3:57 PM EDT - 1 day ago

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately

Aug 18, 2025, 1:28 PM EDT - 3 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Aug 18, 2025, 7:05 AM EDT - 3 days ago

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Aug 14, 2025, 3:55 PM EDT - 7 days ago

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 14, 2025, 7:00 AM EDT - 7 days ago

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 24, 2025, 5:36 PM EDT - 4 weeks ago

Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, Buying

Jul 24, 2025, 8:00 AM EDT - 4 weeks ago

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

Jul 19, 2025, 2:19 PM EDT - 4 weeks ago

UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

Jul 8, 2025, 8:30 AM EDT - 6 weeks ago

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 7, 2025, 7:00 AM EDT - 6 weeks ago

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 30, 2025, 7:05 AM EDT - 7 weeks ago

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Jun 17, 2025, 7:00 AM EDT - 2 months ago

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Jun 10, 2025, 6:00 AM EDT - 2 months ago

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

May 22, 2025, 7:00 AM EDT - 3 months ago

Unicycive Therapeutics to Present at Upcoming Investor Conferences

May 21, 2025, 7:00 AM EDT - 3 months ago

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

May 14, 2025, 7:15 AM EDT - 3 months ago

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 7:00 AM EDT - 5 months ago

Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia

Feb 20, 2025, 7:00 AM EST - 6 months ago

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

Jan 28, 2025, 7:00 AM EST - 7 months ago

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

Jan 7, 2025, 7:00 AM EST - 8 months ago

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Nov 21, 2024, 7:00 AM EST - 9 months ago

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:15 AM EST - 10 months ago

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 10 months ago

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Oct 28, 2024, 7:03 AM EDT - 10 months ago

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

Oct 16, 2024, 4:35 PM EDT - 11 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

Oct 14, 2024, 7:03 AM EDT - 11 months ago

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

Oct 9, 2024, 7:03 AM EDT - 11 months ago

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

Sep 24, 2024, 7:03 AM EDT - 11 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Sep 16, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

Sep 5, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Aug 26, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024

Aug 14, 2024, 7:10 AM EDT - 1 year ago

Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)

Jul 11, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jul 10, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

Jul 1, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Joins Russell Microcap® Index

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial

May 28, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

May 23, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference

May 15, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

May 13, 2024, 4:16 PM EDT - 1 year ago

Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

donkeykongreturns Aug. 22 at 1:52 AM

0 · Reply

Earth4thewin Aug. 21 at 4:18 PM

$UNCY to all those that got scared into selling their shares on the last dip 😔

0 · Reply

anan1 Aug. 21 at 3:12 PM

$UNCY When is the next dilution Gupta? He needs to go to Jail.

0 · Reply

Howdy123_ Aug. 21 at 2:53 PM

$UNCY they're waiting for any run up to dilute into

0 · Reply

Howdy123_ Aug. 21 at 2:02 PM

$UNCY this thing looks like it's about to drop down a cliff

0 · Reply

Howdy123_ Aug. 21 at 1:39 PM

$UNCY they're probably at 23 million outstanding shares now

0 · Reply

Howdy123_ Aug. 21 at 1:35 PM

$UNCY Dowwwwwwwwn it goes

0 · Reply

zawojak Aug. 21 at 6:30 AM

$UNCY never fails to disappoint, as good as management.

0 · Reply

TheYoungGeologist Aug. 20 at 9:56 PM

$UNCY

0 · Reply

Howdy123_ Aug. 20 at 8:08 PM

$UNCY we have a runner -- ending up +0.5% 🙏🙏. Great job UNCY team

1 · Reply

Howdy123_ Aug. 20 at 7:44 PM

$UNCY this will be less than $3 by end of the week

1 · Reply

Howdy123_ Aug. 20 at 6:56 PM

$UNCY probably going to sell out my positions at a loss now and start a short position on this garbage 🗑️. Chart looks ugly and management is terrible. Might be time to make some easy money with Gupta

0 · Reply

Howdy123_ Aug. 20 at 6:23 PM

$UNCY come on Gupta bring this to zero!

0 · Reply

Howdy123_ Aug. 20 at 6:04 PM

$UNCY let's go Gupta!!!!!! Bring it down

0 · Reply

Howdy123_ Aug. 20 at 5:37 PM

$UNCY after they complete diluting their 50 million atm, they should instantly open up another one to continue the dilution machine going

0 · Reply

Howdy123_ Aug. 20 at 4:56 PM

$UNCY Do we see over a 1% gain today from the most incompetent, corruptly run company??????? 🤯

0 · Reply

OldManLogan Aug. 20 at 4:54 PM

$UNCY I'm a watcher at this point, not a holder, but are you telling me that they issued a ER on August 14th saying that they had sufficient cash until end of 2026 and then the next day they quietly publish a 8K disclosing that they diluted they shares by 25%? How are they able to make a material change like that without a PR? Seems shady.

1 · Reply

Howdy123_ Aug. 20 at 4:28 PM

$UNCY spoke too soon😂😂😂

0 · Reply

Howdy123_ Aug. 20 at 4:08 PM

$UNCY up half a percent again today!!!!!!!!!

0 · Reply

Bullvbearss Aug. 20 at 2:14 AM

$UNCY they diluted 25% of the shares at $4.56 per their 8k raising like $16-18M -- which is what caused the price drop not The lawsuit.

4 · Reply

Hstar Aug. 20 at 12:14 AM

$UNCY lawyers are a funny business. Lawsuits tend to follow when companies are at a pivotal stage. This is when they make the most money. No one’s really in it for the good. The page will turn soon enough 🚀

1 · Reply

Howdy123_ Aug. 19 at 5:46 PM

$UNCY on their way to max out their 400 million outstanding shares they're allowed to dilute to 🔥🔥🔥🔥🔥

0 · Reply

Market Cap	51.45M
Revenue (ttm)	0.00
Net Income (ttm)	-36.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	460,000
Avg Vol	790,500
Day's Range	N/A - N/A
Shares Out	12.64M
Stochastic %K	35%
Beta	1.88
Analysts	Strong Sell
Price Target	$37.86